GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Cost of Goods Sold

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Cost of Goods Sold : $0.00 Mil (TTM As of Dec. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Cost of Goods Sold?

Sunesis Pharmaceuticals's cost of goods sold for the three months ended in Dec. 2020 was $0.00 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2020 was $0.00 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Sunesis Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2020 was %.

Cost of Goods Sold is also directly linked to Inventory Turnover.


Sunesis Pharmaceuticals Cost of Goods Sold Historical Data

The historical data trend for Sunesis Pharmaceuticals's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Cost of Goods Sold Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sunesis Pharmaceuticals Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals  (NAS:SNSS) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Sunesis Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2020 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Sunesis Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2020 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Sunesis Pharmaceuticals Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Executives
Steve Carchedi director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto director 58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum director 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young director
Homer L Pearce director 84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt director, officer: See Remarks C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump director
Tina Gullotta officer: VP, Finance SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Headlines

From GuruFocus

Sunesis Pharmaceuticals Provides Corporate Update

By Marketwired Marketwired 07-08-2020

Sunesis Announces Pricing of $12 Million Offering of Common Stock

By Marketwired Marketwired 07-29-2020